The two have partnered with the ON LiMiT research project
Liva Healthcare, a specialist in digital behaviour change solutions for cardiometabolic health, and NUPO, a provider of clinically formulated diet solutions supporting the study’s dietary intervention, have partnered with the ON LiMiT research project, a national study investigating lifestyle-driven remission of type 2 diabetes.
Under this collaboration, Liva will develop and deliver its technology platform and utilise its insights from its work on NHS England Type 2 diabetes remission programmes with NUPO to support participant engagement, behaviour tracking, and long-term lifestyle improvement.
ON LiMiT is a Danish intervention study investigating the maintenance of remission of type 2 diabetes through weight loss, diet, and exercise. The project runs from 2025 to 2030 and will be conducted near the study sites in Aarhus, Odense, and Copenhagen.
The project has brought together Danish research institutions, including the Steno Diabetes Centre Aarhus, Aarhus University, Steno Diabetes Centre Copenhagen, Steno Diabetes Centre Odense, Bispebjerg Hospital, as well as the Department of Nutrition, Sports and Exercise and the Novo Nordisk Foundation Centre for Basic Metabolic Research at the University of Copenhagen.
The project will be one of the largest remission studies in the world that includes diet and exercise, and will involve 1,500 participants and will be funded with over DKK 100 million by the Novo Nordisk Foundation. The program will explore combinations of dietary strategies and physical activity regimes to identify which behaviour modifications most effectively support maintenance of diabetes and long-term health outcomes.
Under the partnership, Liva’s technology will be adapted to support participant interactions, including digital coaching, behaviour tracking, and adaptive insights to help indivudials personalise their lifestyle actions while NUPO will provide an intervention for the first 12 weeks of the program to support metabolic improvement and reset as well as an effective weight loss, which hopes to trigger remission for most type 2 patients.
Martin Møller Paarse, CEO at Liva Healthcare, said, “Liva Healthcare is proud to support ON LiMiT with advanced digital tools and the learnings from successful type 2 diabetes remission programmes. This partnership aligns with our mission to empower sustainable, effective lifestyle change at scale. Together with Denmark’s research leaders, we are committed to advancing evidence-based solutions that improve health outcomes for individuals with type 2 diabetes.”
Peter Wedelheim, CEO of NUPO, said, “We are proud to have been selected as the dietary intervention partner in ON LiMiT. Type 2 diabetes remission does not start with technology or medication – it starts with a decisive metabolic reset. In this study, NUPO delivers a structured, clinically validated dietary intervention that creates the physiological conditions for remission in the critical first phase. Combined with Liva’s digital support and Denmark’s leading research institutions, ON LiMiT has the potential to redefine how lifestyle-driven remission is achieved and sustained at scale.”
Professor Søren Gregersen, Steno Diabetes Centre Aarhus and principal investigator of the ON LiMiT project, said, “Combining rigorous clinical research with cutting-edge digital tools can help unlock new insights into how lifestyle influences diabetes remission. Digital platforms like Liva’s enable us to capture rich behavioural data and sustain participant engagement over extended periods.”
Bettina Ewers, clinical researcher and lead of the dietary interventions in ON LiMiT said, “Research and clinical practice shows that structured use of very low-calorie diets can be a powerful catalyst for weight loss and metabolic improvements. By using diet formulas such as NUPO in ON LiMiT, we build on this knowledge while creating a clear and manageable starting point that supports both remission of type 2 diabetes and participant motivation.”
